The BCR-ABL fusions were observed in only five suspected CML patients, out of 10 patients, and one CML patient under imatinib therapy (during a 5-year period) (Figs.1, -3). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.